ArticleDiabetes spectrum : a publication of the American Diabetes Association2024
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know.
Article in Diabetes spectrum : a publication of the American Diabetes Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease.Hepatology (Baltimore, Md.) · 2026Review
- Reimbursement restrictions reduce liver fibrosis screening in adults with diabetes in Ontario: a population-based interrupted time series analysis.Scientific reports · 2026Article
- Elevated FIB-4 index as a risk marker within the KDIGO framework in patients with type 2 diabetes and hypertension.BMJ open diabetes research & care · 2026Article
- Article
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- Association of one-hour postload plasma glucose combined with metabolic dysfunction-associated steatotic liver disease and FIB-4 screening positivity with elevated LDL cholesterol and cerebrovascular stenosis.Frontiers in endocrinology · 2026Article
- A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis.The Lancet regional health. Europe · 2025Review
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025.Diabetes care · 2025Review
- A real-world study of polyenyl phosphatidylcholine in the management of patients with metabolic dysfunction-associated fatty liver disease in China clinical practice.Frontiers in medicine · 2025Article
- Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action.Diabetes spectrum : a publication of the American Diabetes Association · 2024Article
- Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care.Diabetes spectrum : a publication of the American Diabetes Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standards of care summarized in clinical practice guidelines for nonalcoholic fatty liver disease (NAFLD) offer clinicians a streamlined diagnostic and management approach based on the best available evidence. These recommendations have changed a great deal in recent years; today, there is a clear focus on screening for the early identification and risk stratification of patients at high risk of steatohepatitis and clinically significant fibrosis to promote timely referrals to specialty care when needed. This article reviews and provides the rationale for current guidelines for NAFLD screening, diagnosis, treatment, and monitoring and addresses barriers to providing evidence-based NAFLD care and how to overcome them. The current paradigm of care calls for primary care clinicians and specialists to work together, within a multidisciplinary care team familiar with obesity and diabetes care, to provide comprehensive management of these complex patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.